{"symbol":"GILD","provider":"yahoo-finance","fetchedAt":"2025-12-22T21:58:30.087Z","asOfDate":"2025-12-22","articles":[{"id":"ab3025c7-c0f6-315e-bbfb-fe74a6a5193a","title":"Gilead Sciences to Present at Upcoming Investor Conference","url":"https://finance.yahoo.com/news/gilead-sciences-present-upcoming-investor-210500713.html","publisher":"Business Wire","publishedAt":"2025-12-22T21:05:00.000Z","relatedTickers":[],"mainIdea":"Gilead Sciences to Present at Upcoming Investor Conference","summary":"Business Wire: Gilead Sciences to Present at Upcoming Investor Conference. FOSTER CITY, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:"},{"id":"7828ab7e-549d-37f4-b0f5-f06022f529b1","title":"Analyst Report: Gilead Sciences, Inc.","url":"https://finance.yahoo.com/m/7828ab7e-549d-37f4-b0f5-f06022f529b1/analyst-report%3A-gilead.html","publisher":"Morningstar Research","publishedAt":"2025-12-22T16:39:43.000Z","relatedTickers":[],"mainIdea":"Analyst Report: Gilead Sciences, Inc.","summary":"Morningstar Research: Analyst Report: Gilead Sciences, Inc.. Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead"},{"id":"e2be9555-250d-35ae-8f81-a7cb8297c7bc","title":"Gilead Sciences Exercises Option With Assembly Bio to License Herpes Drugs","url":"https://finance.yahoo.com/news/gilead-sciences-exercises-option-assembly-143314192.html","publisher":"MT Newswires","publishedAt":"2025-12-22T14:33:14.000Z","relatedTickers":[],"mainIdea":"Gilead Sciences Exercises Option With Assembly Bio to License Herpes Drugs","summary":"MT Newswires: Gilead Sciences Exercises Option With Assembly Bio to License Herpes Drugs. Gilead Sciences (GILD) said Monday that it has exercised its option to exclusively license Assembly"}]}
